Rhythm Pharmaceuticals (RYTM) Stock Price, News & Analysis

Company Overview

Rhythm Pharmaceuticals, Inc. is a clinical‐stage biotechnology company dedicated to developing targeted therapies for rare genetic diseases of obesity and metabolic dysfunction. The company’s research focuses on the melanocortin‐4 receptor (MC4R) pathway, which plays a central role in regulating appetite, energy expenditure and body weight. Using proprietary peptide technology, Rhythm aims to provide precision treatments to patients with specific genetic variants that disrupt normal weight regulation.

The company’s lead investigational product, setmelanotide, is a selective MC4R agonist designed to restore signaling in patients with deficiencies in genes such as POMC, LEPR and PCSK1. Rhythm has advanced multiple Phase 3 clinical trials for setmelanotide and is pursuing regulatory approvals in both the United States and the European Union. In addition to its lead program, the company is exploring opportunities in related rare obesity indications and branching into other metabolic disorders tied to melanocortin pathway dysfunction.

Founded in 2013 and headquartered in Boston, Massachusetts, Rhythm Pharmaceuticals is led by a management team with extensive experience in drug development, regulatory strategy and commercialization of therapies for rare diseases. The company maintains a robust intellectual property portfolio around its peptide technology and collaborates with academic institutions and patient advocacy groups to advance understanding of rare genetic forms of obesity. Rhythm’s work underscores a commitment to precision medicine approaches that address the root causes of metabolic disorders.

Key Stats

• Today's Range: $91.05 to $95.11
• 50-Day Range: $75.82 to $99.15
• 52-Week Range: $55.31 to $122.20
• Volume: 474,412 shs
• Average Volume: 784,085 shs
• Market Capitalization: $6.52 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $131.63
• Consensus Rating: Moderate Buy

Rhythm Pharmaceuticals Stock Analysis - MarketRank™

Rhythm Pharmaceuticals scored higher than 52% of companies evaluated by MarketBeat, and ranked 508th out of 856 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Rhythm Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.84, and is based on 1 strong buy rating, 15 buy ratings, 2 hold ratings, and 1 sell rating.

Upside Potential

Rhythm Pharmaceuticals has a consensus price target of $131.19, representing about 40.0% upside from its current price of $93.68.

Amount of Analyst Coverage

Rhythm Pharmaceuticals has been the subject of 13 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Rhythm Pharmaceuticals are expected to grow in the coming year, from ($3.08) to ($0.24) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Rhythm Pharmaceuticals is -30.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Rhythm Pharmaceuticals is -30.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Rhythm Pharmaceuticals has a P/B Ratio of 45.04. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

12.21% of the float of Rhythm Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Rhythm Pharmaceuticals has a short interest ratio ("days to cover") of 12.81, which indicates bearish sentiment.

Change versus previous month

Short interest in Rhythm Pharmaceuticals has recently increased by 2.70%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Rhythm Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Rhythm Pharmaceuticals does not have a long track record of dividend growth.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 0.70

News Sentiment

Rhythm Pharmaceuticals has a news sentiment score of 0.70. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 18 news articles for Rhythm Pharmaceuticals this week, compared to 5 articles on an average week.

Search Interest

Only 2 people have searched for RYTM on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

MarketBeat Follows

Only 3 people have added Rhythm Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.9 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Rhythm Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,017,217.00 in company stock.

Percentage Held by Insiders

6.10% of the stock of Rhythm Pharmaceuticals is held by insiders.

Percentage Held by Institutions

Rhythm Pharmaceuticals has minimal institutional ownership at this time.

RYTM Stock Analysis - Frequently Asked Questions

How have RYTM shares performed this year?

Rhythm Pharmaceuticals' stock was trading at $107.04 at the start of the year. Since then, RYTM stock has decreased by 12.5% and is now trading at $93.68.

How were Rhythm Pharmaceuticals' earnings last quarter?

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) posted its quarterly earnings results on Tuesday, May, 5th. The company reported ($0.83) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.86) by $0.03. The company's quarterly revenue was up 83.8% on a year-over-year basis.
Read the conference call transcript.

When did Rhythm Pharmaceuticals IPO?

Rhythm Pharmaceuticals (RYTM) raised $106 million in an IPO on Thursday, October 5th 2017. The company issued 7,050,000 shares at $14.00-$16.00 per share. Morgan Stanley, BofA Merrill Lynch and Cowen served as the underwriters for the IPO and Needham was co-manager.

Who are Rhythm Pharmaceuticals' major shareholders?

Top institutional shareholders of Rhythm Pharmaceuticals include Pictet Asset Management Holding SA (0.98%), Candriam S.C.A. (0.68%), Bank of New York Mellon Corp (0.43%) and Hillsdale Investment Management Inc. (0.06%). Insiders that own company stock include David P Meeker, Hunter C Smith, Yann Mazabraud, Pamela J Cramer, Joseph Shulman, Jennifer Kayden Lee, Alastair Garfield, Lynn A Tetrault, Jennifer L Good and Christopher Paul German.
View institutional ownership trends.

How do I buy shares of Rhythm Pharmaceuticals?

Shares of RYTM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Rhythm Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Rhythm Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Netflix (NFLX), Tesla (TSLA) and Palo Alto Networks (PANW).

Company Calendar

• Last Earnings: 5/05/2026
• Today: 5/06/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:RYTM
• CIK: 1649904
• Web: www.rhythmtx.com
• Phone: (857) 264-4280
• Fax: 857-264-4299
• Employees: 140
• Year Founded: 2008

Price Target and Rating

• Average Price Target for Rhythm Pharmaceuticals: $131.63
• High Price Target: $157.00
• Low Price Target: $88.00
• Potential Upside/Downside: +39.3%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.84
• Research Coverage: 19 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.11)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$196.54 million
• Net Margins: -103.57%
• Pretax Margin: -103.31%
• Return on Equity: -266.56%
• Return on Assets: -45.01%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.41
• Quick Ratio: 4.16

Sales & Book Value

• Annual Sales: $189.76 million
• Price / Sales: 34.11
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.08 per share
• Price / Book: 45.41

Miscellaneous

• Outstanding Shares: 68,530,000
• Free Float: 64,350,000
• Market Cap: $6.47 billion
• Optionable: Optionable
• Beta: 1.94